Phase II study of Monarch eTNS (NeuroSigma) shows benefits for Epilepsy
New results from a Phase II clinical study for the use of Monarch external Trigeminal Nerve Stimulation (eTNS), from NeuroSigma, for the treatment of drug-resistant Epilepsy demonstrated that among patients receiving eTNS there were significant reductions in seizure frequency over the course of the 18-week study. Patients receiving eTNS also demonstrated significant improvements in mood, making eTNS unique among epilepsy therapies. This double-blind randomized active-control trial included fifty subjects.
In September 2012, NeuroSigma received CE Mark approval for the adjunctive treatment of Epilepsy and major depressive disorder, for adults and children 9 years and older. The latest study, led by Christopher M. DeGiorgio, M.D., Professor of Neurology at the University of California, Los Angeles (UCLA) and Vice President of Neurology at NeuroSigma, was published online in the January 30, 2013 issue of Neurology. See: "Randomized controlled trial of trigeminal nerve stimulation for drug-resistant epilepsy" Christopher M. DeGiorgio et al. Neurology, January 30, DOI:10.1212/WNL.0b013e318285c11a
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.